Finoriq research workspace
ATOSSA THERAPEUTICS, INC. (ATOS) Institutional Holdings & 13F Ownership
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in. Review ATOS institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
- Company
- ATOSSA THERAPEUTICS, INC. (ATOS)
- Ticker
- ATOS
- Market Cap
- $21.7M
- Latest Price
- $2.52
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.